JMEA News Flash

September 16, 2008

FDA Clears JMEA Corporation's Cannulated Bone Screw System for Knee Reconstruction

ROCKVILLE, MD, Sept. 16, 2008 (JMEA Corporation) -- JMEA Corporation received clearance from the FDA to market its cannulated bone screw system for knee reconstruction on August 20, 2008. At the end of July, JMEA provided the FDA with independent test data on two types of its screws, which showed up to 24% better performance over its competitor's product. This product is the first in a series of JMEA products focused on the sports medicine and outpatient surgery center markets. Many of the business model processes, designs and suppliers will be common across this series of products.

"What we are doing for this product can be reused for our other products in this market space," said Jack Yeh, President and CEO of JMEA. "We are working with our suppliers to manufacturer this product and will make sure that we can leverage aspects of this system to the next set of products."

About JMEA

JMEA is an early stage medical device company focused on the development and commercialization of orthopedic implants. JMEA is developing proprietary technologies along with an innovative business model. Currently, JMEA has patent applications filed and pending in the spine, sports medicine, knee arthroplasty and bone fixation technology areas.